Twenty-three patients had sufficient pre-treatment tumour tissue as well as plasma DNA available to identify and quantify KRAS mutations, 14 of the 23 (61%) patients had mutKRAS ctDNA detected (8 in the concomitant arm, 6 in the sequential arm). Here, KRAS is linked to neoplasm.